PODD Stock Benefits From the Launch of Omnipod 5 in Canada
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
Insulet Gains 62.9% in a Year: What's Driving the Stock?
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
Insulet Leans Bullish (Technical Analysis)
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with the PPO line above zero indicating positive long-term momentum. Volume analysis shows neutral to slightly bullish accumulation by institutional investors, with recent high volume supporting bullish price action.
Insulet Sales Keep Rising
Insulet Corporation (PODD) continues its strong sales and growth trend.
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02.
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5.
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matt Taylor - Jefferies Phillip Dantoin - Piper Sandler Chris Pasquale - Nephron Research Joanne Wuensch - Citi Operator Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago.
Insulet beats quarterly profit estimates on insulin pump demand
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
